insights_auto
Hvorfor har GIS gått ned? 2,58%?
Gå mer i dybdenchevron_right
GIS:FRA
Gilead Sciences, Inc
150,36 €
arrow_downward
−2,58%(−3,98) 1 D
19. nov., 22:00:00 GMT+1 · EUR
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for GIS …
Åpne
152,66 €
Høy
154,22 €
Lav
150,36 €
Markedsverdi
206,55 mrd.
Snittvolum
275,00
Volum
67,00
52 u høy
157,14 €
52 u lav
100,42 €
Antall ansatte
17k
Åpne
152,66 €
Høy
154,22 €
Lav
150,36 €
Markedsverdi
206,55 mrd.
Snittvolum
275,00
Volum
67,00
52 u høy
157,14 €
52 u lav
100,42 €
Antall ansatte
17k
Nyhetssaker
Fra nettkilder og nyhetspartnere
MarketWatch
·
for 1 time siden
Gilead Sciences Inc. stock outperforms competitors despite losses on the day
ad-hoc-news.de
·
for 7 timer siden
Gilead Sciences stock: HIV growth faces Biktarvy pricing risk
JournalArta
·
for 16 timer siden
Gilead Sciences (GILD) Stock: $168.98, Down 0.75% Nov 18
GuruFocus
·
for 1 døgn siden
Gilead Sciences (GILD) CFO Andrew Dickinson Sells 3,000 Shares
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Om Gilead Sciences, Inc
Administrerende direktørDaniel O'Day
Ansatte17k
Grunnlagt22. juni 1987
HovedkontorFoster City, California, USA
SektorHealth Care
Bransje-
Nettstedgilead.com